Pranlukast

Pranlukast
Clinical data
Trade names	Onon (オノン)
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	R03DC02 (WHO) ;
Pharmacokinetic data
Metabolism	Hepatic (mainly CYP3A4)
Elimination half-life	1.5 hours
Identifiers
	IUPAC name N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-chromen-8-yl]-4-(4-phenylbutoxy)benzamide;
CAS Number	103177-37-3 ;
PubChem CID	4887;
IUPHAR/BPS	3634;
DrugBank	DB01411 ;
ChemSpider	4718 ;
UNII	TB8Z891092;
ChEMBL	ChEMBL21333 ;
CompTox Dashboard (EPA)	DTXSID3043782 ;
ECHA InfoCard	100.236.084
Chemical and physical data
Formula	C27H23N5O4
Molar mass	481.512 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(Nc2cccc3c(=O)cc(c1nn[nH]n1)oc23)c5ccc(OCCCCc4ccccc4)cc5;
	InChI InChI=1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32) ; Key:NBQKINXMPLXUET-UHFFFAOYSA-N ;
	(verify)

Pranlukast (brand name Onon, オノン) is a cysteinyl leukotriene receptor-1 antagonist. This drug works similarly to Merck & Co.'s montelukast (Singulair). It is widely used in Japan.

Medications of this class, which go under a variety of names according to whether one looks at the American, British or European system of nomenclature, have as their primary function the antagonism of bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.^[2]

Medications of this group are normally used as an adjunct to the standard therapy of inhaled steroids with inhaled long- and/or short-acting beta-agonists. There are several similar medications in the group; all appear to be equally effective. Pranlukast is also reported as potential inhibitor of Mycobacterium tuberculosis infection in experimental models.^[3]

^ ^a ^b Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (April 2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metabolism and Pharmacokinetics. 21 (2): 133–139. doi:10.2133/dmpk.21.133. PMID 16702733. Archived from the original on 2008-09-17.
^ Singh RK, Tandon R, Dastidar SG, Ray A (November 2013). "A review on leukotrienes and their receptors with reference to asthma". The Journal of Asthma. 50 (9): 922–931. doi:10.3109/02770903.2013.823447. PMID 23859232. S2CID 11433313.
^ Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A (April 2018). "An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy". EMBO Molecular Medicine. 10 (4): e8038. doi:10.15252/emmm.201708038. PMC 5887547. PMID 29483133.

[Nakade-1] Nakade S, Ueda S, Ohno T, Nakayama K, Miyata Y, Yukawa E, Higuchi S (April 2006). "Population pharmacokinetics of pranlukast hydrate dry syrup in children with allergic rhinitis and bronchial asthma". Drug Metabolism and Pharmacokinetics. 21 (2): 133–139. doi:10.2133/dmpk.21.133. PMID 16702733. Archived from the original on 2008-09-17.

[SinghTandon2013-2] Singh RK, Tandon R, Dastidar SG, Ray A (November 2013). "A review on leukotrienes and their receptors with reference to asthma". The Journal of Asthma. 50 (9): 922–931. doi:10.3109/02770903.2013.823447. PMID 23859232. S2CID 11433313.

[Mishra_A_2018-3] Mishra A, Mamidi AS, Rajmani RS, Ray A, Roy R, Surolia A (April 2018). "An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: Implications to a novel combinatorial therapy". EMBO Molecular Medicine. 10 (4): e8038. doi:10.15252/emmm.201708038. PMC 5887547. PMID 29483133.

[1]

[2]

[3]